Literature DB >> 12882895

Fenofibrate monotherapy induced rhabdomyolysis.

Billie J Barker, Roger R Goodenough, James M Falko.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882895     DOI: 10.2337/diacare.26.8.2482

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  10 in total

Review 1.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Antidyslipidemic effect and antioxidant activity of anthraquinone derivatives from Rheum emodi rhizomes in dyslipidemic rats.

Authors:  Sunil K Mishra; Shashi Tiwari; Atul Shrivastava; Shishir Srivastava; Goutam K Boudh; Shivendra K Chourasia; Upma Chaturvedi; Snober S Mir; Anil K Saxena; Gitika Bhatia; Vijai Lakshmi
Journal:  J Nat Med       Date:  2013-12-17       Impact factor: 2.343

3.  Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.

Authors:  M Ledl; J Hohenecker; C Francesconi; I Roots; M F Bauer; M Roden
Journal:  Diabetologia       Date:  2005-08-17       Impact factor: 10.122

4.  Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids.

Authors:  Paul S Phillips; Theodore P Ciaraldi; Dong-Lim Kim; M Anthony Verity; Tanya Wolfson; Robert R Henry
Journal:  Endocrine       Date:  2008-12-03       Impact factor: 3.633

5.  Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.

Authors:  Ramazan Danis; Sami Akbulut; Sehmus Ozmen; Senay Arikan
Journal:  Case Rep Med       Date:  2010-07-25

6.  Rhabdomyolysis: a case study exploring the possible side effect of lipid lowering medication by a HIV positive patient taking a protease inhibitor.

Authors:  Diana De Carvalho; Mark Citro; Anthony Tibbles
Journal:  J Can Chiropr Assoc       Date:  2008-12

7.  Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection.

Authors:  Neha Sehgal; Kanhaiya Lal Kumawat; Anirban Basu; Vijayalakshmi Ravindranath
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

Review 8.  Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.

Authors:  Dawei Wang; Yanqiu Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

Review 9.  Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

Authors:  Jianyong Wu; Yan Song; Heng Li; Jianghua Chen
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 3.064

Review 10.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.